Cancers With MET Genomic Alterations Terminated Phase 1 Trials for Altiratinib (DB17191)

IndicationStatusPhase
DBCOND0086870 (Cancers With MET Genomic Alterations)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02228811A Study of DCC-2701 in Participants With Advanced Solid TumorsTreatment